A Leading Global Molecular Diagnostic Platform

  • Contribute to the early detection and prevention of infectious disease transmission

  • Leverage our proprietary Antisense molecular RNA diagnostic platform across multiple infectious disease diagnostic categories

  • Create highly accurate, quick, affordable, easy to administer and minimally invasive disease diagnostic testing kits that will democratize testing for use at point of care and in home

Platform Direction

The company’s Antisense molecular diagnostic platform is being developed for use at Point of Care (POC) to test on-site for a wide range of viral and other diseases.

The Company’s first product is an Antisense molecular Point of Care (POC) diagnostic test kit that accurately, quickly and affordably detects Covid-19 in less than 5 minutes.

Applications & Uses

Deployed at the point of entry of high traffic venues such as airports, shopping malls, office buildings, sporting venues, manufacturing plants, hospitals, pharmacies, nursing and long-term care homes the Antisense POC molecular diagnostic test kit will contribute to safe reopening of the economy.

Office Buildings
Shopping Malls
Manufacturing Sites
Nursing/ Care Homes
Sporting Venues

Exclusive Global License

Board-Certified Internist and Renowned Professional Sports Team Physician, Dr. Michael S. Farber, Joins RNA Disease Diagnostics’ Advisory Board

September 2, 2021

RNA Disease Diagnostics, Inc. (RNADD), a company developing a best-in-class molecular diagnostics platform to democratize point-of-care and home-use infectious disease detection, announced today the appointment of Michael S. Farber, M.D. to its Advisory Board.

Read More

Accomplished Healthcare Industry Veteran, Richard G. Ganz, Joins RNA Disease Diagnostics’ Board of Directors

July 8, 2021

RNA Disease Diagnostics, Inc. (RNADD) announced today the appointment of Richard G. Ganz to its Board of Directors. Mr. Ganz brings more than forty years of executive experience to RNADD, having worked with businesses ranging from venture-backed startups to major international healthcare companies.

Read More